GLP-1 receptor agonists reduce osteoarthritis pain through mechanisms beyond weight loss.
- Current status
- Insufficient evidenceEvidence stable · Osteoarthritis
- Why
- STEP 9 showed large pain reduction in people with obesity (mean BMI 40) alongside 13.7% weight loss. Weight loss itself relieves knee OA pain, and no analysis separated the two. No data in normal-weight people with OA.
- What would change it
- A trial in non-obese OA patients, or a weight-matched comparison.
- Linked studies
- 2 · 1 consistent, but doesn't test the claim · 1 doesn't directly test the claim
- Last updated
- Sep 13, 2026
The status is the collection's own judgment on its assessment scale, not a GRADE certainty rating and not medical advice.
01The evidence
The evidence, sorted by what it shows
Consistent, but doesn't test the claim (1)
- Once-Weekly Semaglutide in Persons with Obesity and Knee OsteoarthritisRandomized trial · 2024 · Study tier 2 · Different population · Benefit · Industry funded
STEP 9: WOMAC pain -41.7 vs -27.5; weight -13.7% vs -3.2%; mediation not tested.
Doesn't directly test the claim (1)
- Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trialsTrial registration · 2026 · Preliminary · Different population · Unclear · Industry funded
Design paper for the TRIUMPH retatrutide (triple GIP/GLP-1/glucagon agonist) trials in adults with obesity, including knee OA protocols; it reports no results and does not test an effect beyond weight loss.
02History
How this assessment has changed
- Insufficient evidenceSep 13, 2026 · Evidence stable
initial curated status